Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

doi:10.1200/JCO.2009.25.0712

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2010

Metcalfe Kelly A, Poll Aletta, Royer Robert, Llacuachaqui Marcia, Tulman Anna, Sun Ping, Narod Steven A

Abstract excerpt

PURPOSE: There are two mutations in BRCA1 and one mutation in BRCA2 that are present in up to 2.5% of Ashkenazi Jewish women. Current guidelines for testing stipulate that a personal or family history of cancer be present to be eligible for testing. To date, population screening in this population has not been suggested. However, this may be rational. Little is known about the appropriateness of testing...

Topics

Breast Neoplasms
Female
Genes, BRCA1
Genes, BRCA2
Humans
Jews
Mass Screening
Mutation

Source

Open in PubMed

Identifiers

PMID: 20008623
DOI: 10.1200/JCO.2009.25.0712

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics